Antiangiogenic Drugs in the Treatment of Advanced Epithelial Ovarian Cancer

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Antiangiogenic Drugs in the Treatment of Advanced Epithelial Ovarian Cancer



Anti-Cancer Agents in Medicinal Chemistry, 12(8): 982-987.

Author(s): Parham Khosravi-Shahi and Luis Cabezon-Gutierrez.

Affiliation: Servicio de Oncologia, Hospital de Torrejon, Calle Mateo Inurria, s/n, Torrejon de Ardoz, 28850. Madrid, Spain.

Abstract

Epithelial ovarian cancer (EOC) accounts for approximately 80-90% of all ovarian cancers, and 75% of the patients are diagnosed with advanced disease (stage III and IV). Front-line systemic chemotherapy improves survival in women with advanced EOC; however, tumor recurrence occurs in almost all advanced EOC patients at a median of 15 months from diagnosis, and 5-year survival is estimated at 10 to 30%. Additionally, around 20% of patients do not respond to standard front-line therapy. Tumoral angiogenesis plays an important role in the pathogenesis of EOC, and its inhibition might improve survival in patients with advanced EOC. High-grade EOC is characterized by overexpression of vascular endothelial growth factor (VEGF), which drives dysfunctional tumor-associated angiogenesis, contributing to high interstitial pressure and increased vascular permeability. Diverse anti-angiogenic drugs are under investigation, and direct targeting of this pathway can be achieved by sequestration of VEGF protein using monoclonal antibodies (bevacizumab) or engineered binding site molecules (aflibercept), blockade of the VEGF receptor-2 with monoclonal antibodies or inhibition of receptor associated tyrosine kinase with low molecular weight inhibitors (cediranib, pazopanib, sorafenib or BIBF-1120).

Keywords:

Bevacizumab, BIBF-1120, VEGF, Angiogenesis, Pazopanib, morphologic, endometrioid, carcinomas, morphologic continuum, tumor progression.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 12
Issue Number: 8
First Page: 982
Last Page: 987
Page Count: 6
DOI: 10.2174/187152012802650020
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science